2848664-42-4
Chemical Structure
QL-1200186
- CAS. Nr.: 2848664-42-4
- Formula:C26H27N7O3
- Molecular Weight:485.54
InChIKey: XRANKYHFKDBBKP-UHFFFAOYSA-N
SMILES: COC(C(C(C=C1)=NN1C)=CC(CCOCC2=NC3=CC=C2)=C4)=C4NC(C=C(N3)N=C5)=C5C(NC)=O
Biological Activity: QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE)[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
QL-1200186 | 99.93% | QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.51
HY-401428TYK2 ligand 3 -
Similarity Score 0.49
HY-173359TYK2 ligand 2 -
Similarity Score 0.48
HY-158340TYK2 ligand 1 -
Similarity Score 0.47
HY-181278Deucravacitinib analog 1 -
Similarity Score 0.47
HY-184866Tyk2-IN-26 -
Similarity Score 0.45
HY-172596TYK2 activator-1 -
Similarity Score 0.45
HY-13917PND-1186 -
Similarity Score 0.45
HY-145111TNK2-IN-1 -
Similarity Score 0.45
HY-169984STyk2-IN-22-d3 -
Explore the MedChemAI to find more analogs
